ERBB2 and cancer: With regard to the latter and given that the combination of PTX plus Tmab is regulated and widely employed in the clinical setting, a DDS composed of alginate and piperazine nanoparticles (NPs) was already developed as vehicle for both the mAb and the taxane in a previous work to target HER2+ cancer cells.